Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Core Insights - Biogen has lowered its full-year adjusted-earnings expectations despite a rise in third-quarter profit driven by its Alzheimer's drug and treatments for rare diseases [1] Financial Performance - The third-quarter profit increased due to strong performance from the Alzheimer's drug and rare-disease treatments [1] - Full-year adjusted-earnings expectations have been cut, indicating potential challenges ahead [1]